➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
McKesson
Baxter
Johnson and Johnson

Last Updated: July 30, 2021

DrugPatentWatch Database Preview

APREPITANT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Aprepitant patents expire, and when can generic versions of Aprepitant launch?

Aprepitant is a drug marketed by Glenmark Pharms Sa, Sandoz, and Torrent. and is included in three NDAs.

The generic ingredient in APREPITANT is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aprepitant

A generic version of APREPITANT was approved as aprepitant by SANDOZ on September 24th, 2012.

  Free Forever Trial

Drug patent expirations by year for APREPITANT
Drug Prices for APREPITANT

See drug prices for APREPITANT

Recent Clinical Trials for APREPITANT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai Children's Medical CenterN/A
PlusVitech S.L.Phase 2
ECONiX Araştırma Analiz ve Danışmanlık A.Ş.Phase 2

See all APREPITANT clinical trials

Paragraph IV (Patent) Challenges for APREPITANT
Tradename Dosage Ingredient NDA Submissiondate
EMEND FOR SUSPENSION;ORAL aprepitant 207865 2016-11-23
EMEND CAPSULE;ORAL aprepitant 021549 2008-11-03

US Patents and Regulatory Information for APREPITANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-001 Oct 12, 2017 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Torrent APREPITANT aprepitant CAPSULE;ORAL 211835-001 Oct 21, 2020 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-001 Sep 24, 2012 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Torrent APREPITANT aprepitant CAPSULE;ORAL 211835-002 Oct 21, 2020 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-002 Oct 12, 2017 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-003 Oct 12, 2017 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-003 Sep 24, 2012 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
McKesson
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.